Delta Sleep-Inducing Peptide

Overview

DSIP was first isolated from the cerebral venous blood of rabbits in a state of sleep induced by thalamic stimulation (Monnier et al., 1974). The isolated peptide induced sleep-like EEG patterns when injected into recipient animals, sparking decades of research. Despite its name, the relationship between DSIP and sleep architecture has proven complex and inconsistent across species and dosing protocols.

Beyond sleep, research has identified DSIP's role in normalizing the cortisol response to stress, reducing basal corticotropin levels, modulating GH secretion, and exerting antioxidant effects. Studies in cancer patients reported analgesic and anti-withdrawal properties, and it has been investigated as a potential treatment for alcohol and opiate withdrawal. Its wide-ranging and sometimes paradoxical effects suggest it acts as a neuromodulator that normalizes rather than simply stimulates or suppresses specific axes.

Mechanism of Action

DSIP modulates limbic system activity and hypothalamic-pituitary function through multiple mechanisms that are incompletely characterized. It appears to normalize glucocorticoid receptor function and the HPA stress response. Possible interactions with opioid receptors may underlie its analgesic and anti-withdrawal properties. Its antioxidant activity involves direct free radical scavenging.

Research Areas

• ●Sleep architecture and slow-wave sleep
• ●HPA axis normalization and stress adaptation
• ●Antioxidant and cytoprotective effects
• ●Opioid and alcohol withdrawal models
• ●GH and LH secretion modulation
• ●Pain modulation research

Storage & Handling

For Research Use Only. This information is provided for educational and research purposes. Delta Sleep-Inducing Peptide is not approved for human consumption, veterinary use, or clinical application. All research must be conducted in accordance with applicable laws and institutional guidelines.